AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
AbbVie (NYSE: ABBV) has commenced construction of a new active pharmaceutical ingredient (API) manufacturing facility in North Chicago, Illinois. The $195 million investment is part of AbbVie's broader $10 billion capital investment plan over the next decade to enhance U.S. manufacturing capabilities.
The facility, expected to be fully operational by 2027, will focus on producing API components for immunology, oncology, and neuroscience medicines. This strategic move will relocate select API production from Europe and Asia to the U.S. The project will create new jobs, adding to AbbVie's existing workforce of 28,000 U.S. employees across all 50 states and Puerto Rico, including 6,000 jobs at 11 manufacturing sites.
AbbVie (NYSE: ABBV) ha avviato la costruzione di un nuovo stabilimento per la produzione di ingredienti farmaceutici attivi (API) a North Chicago, Illinois. L'investimento di 195 milioni di dollari fa parte del più ampio piano di investimenti in capitale da 10 miliardi di dollari previsto nei prossimi dieci anni per potenziare le capacità manifatturiere statunitensi.
Lo stabilimento, che dovrebbe diventare operativo al 100% entro il 2027, si concentrerà sulla produzione di componenti API per farmaci in immunologia, oncologia e neuroscienze. Questa mossa strategica sposterà la produzione API selezionata dall'Europa e dall'Asia verso gli Stati Uniti. Il progetto creerà nuovi posti di lavoro, sommando a una forza lavoro esistente di 28.000 dipendenti negli Stati Uniti distribuiti in tutti i 50 stati e a Porto Rico, tra cui 6.000 posti di lavoro in 11 siti di produzione.
AbbVie (NYSE: ABBV) ha iniciado la construcción de una nueva instalación de fabricación de ingrediente farmacéutico activo (API) en North Chicago, Illinois. La inversión de 195 millones de dólares forma parte del plan de inversión de 10 mil millones de dólares en capital de AbbVie para la próxima década, con el objetivo de mejorar las capacidades de fabricación en Estados Unidos.
La instalación, que se espera completamente operativa para 2027, se centrará en producir componentes API para medicamentos en inmunología, oncología y neurología. Esta iniciativa estratégica desplazará parte de la producción de API desde Europa y Asia hacia Estados Unidos. El proyecto creará nuevos empleos, aumentando la plantilla existente de 28.000 empleados en EE. UU. repartidos en los 50 estados y Puerto Rico, incluyendo 6.000 puestos en 11 sitios de manufactura.
AbbVie (NYSE: ABBV)가 북시카고(일리노이주)에서 새로운 활성의약품 원료(API) 제조시설 건설에 착수했습니다. 1.95억 달러의 투자는 향후 10년간 미국 제조 역량을 강화하기 위한 AbbVie의 100억 달러 규모의 자본 투자 계획의 일환입니다.
이 시설은 2027년까지 완전 가동될 것으로 예상되며 면역학, 종양학, 신경과학 의약품의 API 구성요소 생산에 중점을 둘 것입니다. 이번 전략적 조치는 일부 API 생산을 유럽 및 아시아에서 미국으로 이전하게 될 것입니다. 이 프로젝트는 신규 일자리를 창출하여 미국 내 50개 주와 푸에르토리코 전역에 걸친 28,000명의 기존 고용인과 11개의 제조시설에서 근무하는 6,000명의 일자리를 포함한 AbbVie의 인력 규모를 확장할 것입니다.
AbbVie (NYSE: ABBV) a commencé la construction d'une nouvelle installation de fabrication d'ingrédients actifs (API) à North Chicago, dans l'Illinois. L'investissement de 195 millions de dollars s'inscrit dans le cadre du plan d'investissement en capital de 10 milliards de dollars sur la prochaine décennie pour renforcer les capacités de fabrication américaines.
L'installation, qui devrait être entièrement opérationnelle d'ici 2027, se concentrera sur la production de composants API pour les médicaments en immunologie, oncologie et neurosciences. Cette démarche stratégique permettra de déplacer une partie de la production d'API depuis l'Europe et l'Asie vers les États‑Unis. Le projet créera de nouveaux emplois et portera l'effectif de l'entreprise à 28 000 employés aux États‑Unis, répartis sur les 50 États et Porto Rico, dont 6 000 postes dans 11 sites de fabrication.
AbbVie (NYSE: ABBV) hat den Bau einer neuen Produktionsanlage für Wirkstoffe (API) in North Chicago, Illinois, begonnen. Die 195-Millionen-Dollar-Investition ist Teil des umfassenderen 10-Milliarden-Dollar-Investitionsplans von AbbVie für das kommende Jahrzehnt, um die US-Herstellungsfähigkeiten zu stärken.
Die Anlage soll voraussichtlich bis 2027 vollständig in Betrieb gehen und sich auf die Herstellung von API-Komponenten für Immunologie-, Onkologie- und Neurowissenschaften-Medikamente konzentrieren. Dieser strategische Schritt wird ausgewählte API-Herstellungen von Europa und Asien in die USA verlagern. Das Projekt wird neue Arbeitsplätze schaffen und die bestehende Belegschaft von 28.000 US-Beschäftigten in allen 50 Bundesstaaten und Puerto Rico erweitern, einschließlich 6.000 Stellen an 11 Fertigungsstandorten.
AbbVie (NYSE: ABBV) بدأت بناء منشأة جديدة لإنتاج المركب النشط دوائياً (API) في نورث شيكاغو، إلينوي. ويعد الاستثمار البالغ 195 مليون دولار جزءاً من خطة AbbVie الأوسع بقيمة 10 مليارات دولار في رأس المال على مدار العقد القادم لتعزيز قدرات التصنيع في الولايات المتحدة.
من المتوقع أن تكون المنشأة قابلة للتشغيل الكامل بحلول عام 2027، وستركز على إنتاج مكونات API للأدوية المناعية والسرطانية والعصبية. ستنقل هذه الخطوة الاستراتيجية بعض إنتاج API من أوروبا وآسيا إلى الولايات المتحدة. سيخلق المشروع وظائف جديدة، ليضاف إلى القوى العاملة الحالية التي تبلغ 28,000 موظف في الولايات المتحدة المنتشرين في جميع الولايات الخمسين وبورتو ريكو، بما في ذلك 6,000 وظيفة في 11 موقع تصنيع.
艾伯维（NYSE: ABBV） 已在美国伊利诺伊州北芝加哥启动新药用活性成分(API) 生产基地的建设。1.95亿美元的投资 是 AbbVie 在未来十年内总计 100亿美元的资本投资计划 的一部分，旨在提升美国的制造能力。
该基地预计将于2027年全面投入运行，将专注于免疫学、肿瘤学和神经科学药物的 API 成分生产。这一战略举措将把部分 API 生产从欧洲和亚洲转移到美国。该项目将创造新岗位，扩大 AbbVie 在全美50个州及波多黎各的现有员工规模至28,000名美国员工，其中在11个制造基地将增加 6,000个岗位。
- Significant $195 million investment in U.S. manufacturing expansion
- Part of larger $10 billion capital investment plan over next decade
- Strategic relocation of API production from Europe/Asia to U.S.
- Creation of new manufacturing jobs in Illinois
- Expansion of capabilities in immunology, oncology, and neuroscience medicine production
- Facility won't be operational until 2027, indicating a long implementation timeline
Insights
AbbVie's $195M US API facility strengthens domestic supply chain, adds jobs, and supports long-term manufacturing independence from overseas sources.
AbbVie's groundbreaking for its $195 million North Chicago API manufacturing facility represents a strategic reshoring initiative that addresses several key industry challenges. This facility will transfer production of select active pharmaceutical ingredients from Europe and Asia to the US, enhancing supply chain resilience – a critical concern since pandemic-related disruptions highlighted vulnerabilities in pharmaceutical manufacturing dependencies.
The investment is part of AbbVie's broader $10+ billion decade-long capital expansion plan for US manufacturing. When operational in 2027, this facility will specifically support AbbVie's core therapeutic areas: immunology, oncology, and neuroscience – representing their highest-value product segments.
Chemical synthesis capabilities for APIs require sophisticated process engineering and quality control systems. By bringing these operations to North Chicago, AbbVie gains greater control over critical manufacturing steps while potentially reducing supply chain complexity and regulatory hurdles associated with cross-border ingredient transfers.
The strategic value extends beyond the immediate facility. AbbVie's decision to expand its manufacturing footprint in its home state of Illinois, where it already employs 11,000 workers, demonstrates confidence in the local workforce and infrastructure. This investment aligns with broader pharmaceutical industry trends toward manufacturing redundancy and geographic diversification of production capabilities to mitigate future supply disruptions.
- New state-of-the-art active pharmaceutical ingredient (API) facility will manufacture immunology, oncology and neuroscience medicines
- Facility expected to be fully operational and serving patients by 2027
-
Milestone marks progress on
AbbVie's long-term commitment to
U.S. manufacturing
"Today's groundbreaking is an important milestone in AbbVie's ongoing campaign to accelerate biopharmaceutical innovation and manufacturing capabilities in the
Active pharmaceutical ingredient manufacturing is a complex and multistep process that involves producing the active components responsible for medications' therapeutic effects. When completed, AbbVie's new North Chicago API facility will expand its chemical synthesis capabilities and enable AbbVie to bring API production for select products from
With a presence in all 50 states and
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter) and YouTube.
|
Media: |
Investors: |
|
Gabby Tarbert |
Liz Shea |
|
(224) 244-0111 |
(847) 935-2211 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-breaks-ground-on-new-north-chicago-active-pharmaceutical-ingredient-manufacturing-facility-302569711.html
SOURCE AbbVie
FAQ
How much is AbbVie investing in the new North Chicago API manufacturing facility?
When will AbbVie's new North Chicago manufacturing facility be operational?
How many U.S. manufacturing jobs does AbbVie currently support?
What is AbbVie's total planned U.S. manufacturing investment over the next decade?
What types of medicines will be manufactured at AbbVie's new North Chicago facility?
